UCB: Third quarter Zyrtec sales in the US | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB: Third quarter Zyrtec sales in the US

Referring to today's announcement from Pfizer of its third quarter results, UCB confirms that the sales of Zyrtec, the number one branded antihistamine in the US, grew 25% to $347 million in the third quarter of 2003, compared to the same period in 2002 (year-to-date turnover of $980 million).

Zyrtec's growth can be attributed in part to strong performance in abroad range of formulations - tablets, syrup, and the 12-hour decongestant formulation - and for both adult and paediatric patients.

Underlying Zyrtec's strong sales performance is the differentiation of its efficacy relative to other products, prescription or OTC.

Contact : Arnaud Denis - Investor Relations Manager
Tel : +32-(0)2-559.92.64 Fax : +32-(0)2-559.95.71

Stay up-to-date on the latest news and information from UCB